- ENDV has developed a viable pain-control solution for those seeking alternatives to highly addictive opioids
- The company’s flagship product is an FDA-cleared, easy-to-place, noninvasive device that delivers pulsed electromagnetic frequencies to targeted area
- In one study, patients treated with Endonovo technology reported a decrease in pain medication by nearly threefold
Amid mounting concern about the alarming opioid-addiction crisis, Endonovo Therapeutics Inc. (OTCQB: ENDV) offers one of the few bright spots on the horizon. Endonovo is the commercial-stage developer of noninvasive Electroceutical(TM) Therapeutic devices designed to target patient pain and inflammation, a viable pain-control solution for those desperately seeking options other than highly addictive drugs.
The crisis is real. The National Institute on Drug Abuse reports that 21% to 29% of patients prescribed opioids for chronic pain misuse them, and more than 130 people in the United States die every day after overdosing on opioids (http://ibn.fm/92SUO). The economic burden of the crisis is also heavy, with prescription opioid misuse alone in the United States totaling $78.5 billion annually including the costs of health care, lost productivity, addiction treatment and criminal justice involvement.
Endonovo provides an alternative. The company’s flagship product, SofPulse(R) Electroceutical(TM) Therapy is an FDA-cleared, easy-to-place, noninvasive device that delivers targeted pulsed electromagnetic field (tPEMF) frequencies to enhance postsurgical recovery. Used as a standalone therapy or integrated into any treatment protocol, SofPulse transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. Patients using SofPulse require significantly fewer prescription medications, potentially decreasing the adverse side effects of opioid medication.
Endonovo’s tPEMF technology is FDA approved for the treatment of post-operative pain and edema, with studies indicating that the technology is at least as effective as NSAIDs in the treatment of pain and swelling. In one study, patients treated with Endonovo tPEMF technology experienced a decrease in pain medication by nearly threefold compared to those who didn’t receive the therapy (http://ibn.fm/jkeC1).
Battery-operated and disposable, SofPulse(R) is a wearable device that delivers electromagnetic pulses either manually or in a preprogrammed mode that automatically provides 15 minutes of therapy every two hours. The pulses go through dressings, casts and clothing, and the convenient device allows a person to remain mobile while still receiving powerful treatment. The treatment can also be integrated into a variety of pain-management, wound-care and post-op protocols.
Endonovo is focused on providing clinical solutions substantiated with research and evidence-based data. The company also strives to be an educational resource for clinicians and has created a research library comprised of the latest clinical data, abstracts and media that focuses on tPEMF technologies. Based on the company’s key technological developments and innovative therapies, Endonovo may represent a significant long-term valuation potential.
For more information, visit the company’s website at www.Endonovo.com
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV